Year : 2021  |  Volume : 6  |  Issue : 1  |  Page : 23-29

Evidence of superiority of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors or angiotensin ii receptor blockers in the heart failure with reduced ejection fraction patient's journey

Department of Cardiovascular, Papa Giovanni XXIII Hospital, Bergamo, Italy

Correspondence Address:
Michele Senni
Department of Cardiovascular, Papa Giovanni XXIII Hospital, Bergamo
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2470-7511.312591

Get Permissions

Sacubitril/valsartan (S/V) is a new drug which has been recently recommended by the international guidelines for the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF). Compared to angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs), S/V is associated with a better cardiovascular outcome, and to a greater beneficial effect on myocardial reverse remodeling. Recent evidence has shown that S/V is not only recommended in chronic patients but it is also approved in the acute setting; moreover, its safety and tolerability have been demonstrated also in the pediatric population. This review summarizes data on the effectiveness and tolerability of S/V in HFrEF patients and offers practical insights to manage this drug in every setting, providing an overview from randomized clinical trials' data to real-world evidence.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded91    
    Comments [Add]    

Recommend this journal